Compare Figs Inc (FIGS) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Revvity Inc — how do they compare? Figs Inc trades at $15.76 (market cap $2.49B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 6.8× Figs Inc's market cap, and Revvity Inc pays a 0.18% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Revvity Inc for 12 Days on average.
| FIGS | RVTY | |
|---|---|---|
Market Cap | $2.49B | $16.98B |
Volume | 5,964,311 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $157.36 |
52-Week Low | $6.90 | $82.26 |
Typical Hold Time | 33 Days | 12 Days |
Enterprise Value | $2.25B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $15.78, up 12.23% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth from $556M in 2024 to $631M in 2025, with net income improving to $34M. Recent Q2 2026 earnings beat expectations by 64%, and international sales surged 67% according to Zacks Research on August 20, 2026. The stock faces valuation concerns with a P/E of 45.39, but analyst consensus targets $18.00 representing 14% upside potential.
Outlook remains positive with projected 2026 revenue of $710M and net income of $62M, though rich valuation requires continued execution. Key risks include competitive pressures and margin sustainability. With 60% analyst buy ratings and improving cash flow projections, FIGS offers growth exposure but demands careful risk management given premium multiples.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
